Skip to main content
SpringerLink
Log in

Pharmacotherapy for Overactive Bladder

An Evidence-Based Approach to Selecting an Antimuscarinic Agent

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Multiple drugs are now available for the treatment of overactive bladder. Currently, the pharmacological approach is to deal with the problem at the neuromuscular junction by attempting to stop the activity of the neurotransmitter with antimuscarinic medications. This article reviews the positive and negative aspects of the agents that are currently available for use in the US. In randomised clinical trials, extended-release formulations of these agents appear as effective as the immediate-release formulations, but are associated with fewer adverse effects. Attempts to use entities that are muscarinic M3 selective antimuscarinic agents have not significantly improved the efficacy, but have reduced the major adverse effect of excessively dry mouth. Dose escalation or titration is addressed to enhance efficacy further. None of these drugs appear to cause significant cardiac or CNS adverse events. This supports the continued use of these agents for overactive bladder symptomatology, as they appear to be effective in reducing symptoms and remain generally well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 2002; 21(2): 167–78

    Article  PubMed  Google Scholar 

  2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20(6): 327–36

    PubMed  CAS  Google Scholar 

  3. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (11 Suppl.): S574–9

    PubMed  CAS  Google Scholar 

  4. Jeong GL, Jae YH, Myung-Soo C, et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol 2002; 9(5): 247–52

    Article  Google Scholar 

  5. Leung HY, Yip SK, Cheon C, et al. Tolterodine and oxybutynin had similar tolerability and efficacy for the treatment of over-active bladder. EROG 2003; 5(2): 88–9

    Google Scholar 

  6. Malone-Lee J, Whately-Smith C. A study of the significance of identifying detrusor instability in the treatment of overactive bladder symptoms [presentation]. 34th meeting of the International Continence Society; 2004 Aug 23–27; Paris

  7. Anderson RU, Brown JS, Mobley D, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161(6): 1809–12

    Article  PubMed  CAS  Google Scholar 

  8. Barkin J, Corcos J, Radomski S, et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004; 26(7): 1026–36

    Article  PubMed  CAS  Google Scholar 

  9. Birns J, Malone-Lee JG, Lukkari E. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10mg once daily) with conventional oxybutynin tablets (5mg twice daily) in patients whose symptoms were stabilized on 5mg twice daily of oxybutynin. BJU Int 2000; 85(7): 793–8

    Article  PubMed  CAS  Google Scholar 

  10. Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000; 95(5): 718–21

    Article  PubMed  CAS  Google Scholar 

  11. van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57(3): 414–21

    Article  PubMed  Google Scholar 

  12. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62(2): 237–42

    Article  PubMed  Google Scholar 

  13. Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005; 27(1): 127–38

    Article  PubMed  CAS  Google Scholar 

  14. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001; 41(6): 636–44

    Article  PubMed  CAS  Google Scholar 

  15. GlaxoSmithKline. VESIcare (solifenacin succinate) prescribing information. GlaxoSmithKline, 2004 Nov

  16. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001; 76(4): 358–63

    PubMed  CAS  Google Scholar 

  17. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78(6): 687–95

    Article  PubMed  CAS  Google Scholar 

  18. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45(4): 420–9

    Article  PubMed  CAS  Google Scholar 

  19. Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU International 2005; 95(4): 580–6

    Article  PubMed  CAS  Google Scholar 

  20. Hill S, Khullar V. Darifenacin, a muscarinic receptor antagonist with selectivity for m3 receptors, reduces incontinence and nocturia in patients with overactive bladder [abstract]. 34th meeting of the International Continence Society; 2004 Aug 23–27; Paris

  21. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005; 95(7): 993–1001

    Article  PubMed  CAS  Google Scholar 

  22. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172(5 I): 1919–24

    Article  PubMed  CAS  Google Scholar 

  23. Chapple CR, Rechberger T, Al Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93(3): 303–10

    Article  PubMed  CAS  Google Scholar 

  24. Chapple C, Jonas U, Chancellor M, et al. New antimuscarinic agent, solifenacin succinate, reduces urgency episodes in over-active bladder: an analysis of over 3000 patients [poster]. EAU Annual Meeting; 2004 Mar 24–27; Vienna

  25. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended-release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464–70

    Article  PubMed  CAS  Google Scholar 

  26. MacDiarmid SA. Overactive bladder: improving the efficacy of anticholinergics by dose escalation. Curr Urol Rep 2003; 4: 446–51

    Article  PubMed  Google Scholar 

  27. Frohlich G, Bulitta M, Strosser W. Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20mg trospium chloride twice daily. Int J Clin Pharmacol Ther 2002; 40(7): 295–303

    PubMed  CAS  Google Scholar 

  28. Zinner N, Auerbach S, Gittelman M, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171(6 I): 2311–5

    Article  PubMed  CAS  Google Scholar 

  29. Rudy D, Cline K, Goldberg K, et al. A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients. 34th meeting of the International Continence Society; 2004 Aug 23–27; Paris

  30. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20(6): 392–9

    PubMed  CAS  Google Scholar 

  31. Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47(4): 337–43

    Article  PubMed  CAS  Google Scholar 

  32. Katz IR, DiFilippo S, Boyce A, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46(1): 8–13

    PubMed  CAS  Google Scholar 

  33. Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48(1): 5–26

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, Houston, Texas, 77030, USA

    Rodney A. Appell

Authors
  1. Rodney A. Appell
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Appell, R.A. Pharmacotherapy for Overactive Bladder. Drugs 66, 1361–1370 (2006). https://doi.org/10.2165/00003495-200666100-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666100-00005

Keywords

Search

Navigation